Arch Therapeutics, Inc.
Arch Therapeutics, Inc.（ARTH）内幕交易
基于 SEC Form 4 的买入/卖出笔数、买卖比与情绪标签；可在本季度与近12个月之间切换；下方为季度图与交易明细。
SEC EDGAR · FMP · ARTH · 截至 2026年6月9日
活动摘要
买入笔数
0
P-Purchase only
卖出笔数
0
近12个月
买卖比
0.00
Buy/Sell (by trades)
整体情绪
Arch Therapeutics, Inc.内部人在过去近12个月买卖活动混合。
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 买入仅计P-Purchase · 卖出仅计S-Sale
截至 2026年6月9日
ARTH 季度内部人买卖趋势
ARTH 内幕交易卖出 · ARTH 内幕交易买入 · 季度活动
Mobile shows last 4Q · Desktop shows full 8Q
▸ 数据来源：SEC EDGAR · Form 3 & 4 · 最近8季度
As of Jun 9, 2026
近期内幕交易记录
ARTH 高管卖出股份 · ARTH 董事内幕交易 · SEC Form 4申报
横向滑动查看全部列
| 日期 | 内部人 | 类型 | 股数 | 总金额 | 申报 |
|---|---|---|---|---|---|
| Aug 31, 2023 | ABRAMS MICHAEL S CHIEF FINANCIAL OFFICER | Purchase | 10,292 | $3K | Form 4 |
| Aug 31, 2023 | Norchi Terrence W PRESIDENT AND CHIEF EXECUTIVE · Director | Purchase | 6,862 | $2K | Form 4 |
| Aug 31, 2023 | Hicks Laurence Director | Purchase | 10,292 | $3K | Form 4 |
| Jul 6, 2022 | ABRAMS MICHAEL S CHIEF FINANCIAL OFFICER | Award | 108,652 | — | Form 4 |
| Jul 6, 2022 | Norchi Terrence W Director | Award | 72,435 | — | Form 4 |
| Jul 30, 2021 | Yrigoyen Dan Vice President, Sales | Award | 150,000 | — | Form 4 |
| Jun 22, 2020 | SULAT JAMES R Director | Other | 454,546 | $37.19B⚡ | Form 4 |
| Jul 19, 2018 | SULAT JAMES R Director | Award | 110,000 | — | Form 4 |
| Jul 19, 2018 | Norchi Terrence W President & CEO · Director | Award | 360,000 | — | Form 4 |
| Jul 19, 2018 | DAVIS RICHARD E CFO & Treasurer | Award | 275,000 | — | Form 4 |
| Jul 19, 2018 | DHILLON AVTAR S Director | Award | 220,000 | — | Form 4 |
| Jul 16, 2018 | SULAT JAMES R Director | Option | 30,000 | $11K | Form 4 |
| Feb 3, 2017 | SULAT JAMES R Director | Award | 200,000 | — | Form 4 |
| Feb 3, 2017 | Norchi Terrence W President & CEO · Director | Award | 650,000 | — | Form 4 |
| Feb 3, 2017 | DHILLON AVTAR S Director | Award | 400,000 | — | Form 4 |
| Feb 3, 2017 | DAVIS RICHARD E CFO & Treasurer | Award | 500,000 | — | Form 4 |
| May 26, 2016 | SULAT JAMES R Director | Purchase | 111,111 | $40K | Form 4 |
| May 3, 2016 | Norchi Terrence W President & CEO · Director | Award | 1,130,000 | — | Form 4 |
| May 3, 2016 | DAVIS RICHARD E CFO & Treasurer | Award | 103,000 | — | Form 4 |
| May 3, 2016 | SULAT JAMES R Director | Award | 30,000 | — | Form 4 |
| May 3, 2016 | DHILLON AVTAR S Director | Award | 737,000 | — | Form 4 |
| Jun 26, 2013 | Norchi Terrence W Pres, CEO, Sec, and Treas · Director | Other | 1,419,076 | — | Form 4 |
| Jun 25, 2013 | DHILLON AVTAR S Director | Other | 160,373 | — | Form 4 |
Norchi Terrence W
PRESIDENT AND CHIEF EXECUTIVE · Director
日期
Aug 31
股数
6,862
均价
$0.28
总金额
$2K
Norchi Terrence W
Pres, CEO, Sec, and Treas · Director
日期
Jun 26
股数
1,419,076
均价
—
总金额
—
▸ 数据来源：SEC EDGAR · Form 4 申报 · ⚡ = 金额≥$100万 · Award/Option 价格显示 —
关于 ARTH 内幕交易
ARTH 内幕交易
Arch Therapeutics, Inc.（ARTH）内幕交易数据来源于公司内部人（包括ARTH）提交的SEC Form 4申报文件。过去12个月内，0位内部人向SEC提交了交易申报。ARTH内部人近期买卖活动混合，这可能反映预设的10b5-1计划执行，而非方向性判断。
如需查看Arch Therapeutics, Inc.机构持仓比例和内部人持股百分比，请访问持仓（Ownership）标签页 → Ownership tab →
常见问题
ARTH 内幕交易 · 5个问题Arch Therapeutics, Inc.（ARTH）的内部人包括高管和董事，如ARTH等。过去12个月内，0位内部人向SEC提交了Form 4交易申报。内部人须在交易日期后2个工作日内完成申报。
▸ 数据来源：FMP /stable/insider-trading/search · SEC EDGAR Form 3 & 4 · RSU归属不计入情绪 · As of Jun 9, 2026